|
1
|
Rich T, Allen RL and Wyllie AH: Defying
death after DNA damage. Nature. 407:777–783. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roos WP and Kaina B: DNA damage-induced
cell death by apoptosis. Trends Mol Med. 12:440–450. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bernstein C, Bernstein H, Payne CM and
Garewal H: DNA repair/pro-apoptotic dual-role proteins in five
major DNA repair pathways: fail-safe protection against
carcinogenesis. Mutat Res. 511:145–178. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herr I and Debatin KM: Cellular stress
response and apoptosis in cancer therapy. Blood. 98:2603–2614.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sanchez-Prieto R, Rojas JM, Taya Y and
Gutkind JS: A role for the p38 mitogen-acitvated protein kinase
pathway in the transcriptional activation of p53 on genotoxic
stress by chemotherapeutic agents. Cancer Res. 60:2464–2472.
2000.PubMed/NCBI
|
|
6
|
Okada H and Mak TW: Pathways of apoptotic
and non-apoptotic death in tumour cells. Nat Rev Cancer. 4:592–603.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maddika S, ande SR, Panigrahi S, et al:
Cell survival, cell death and cell cycle pathways are
interconnected: implications for cancer therapy. Drug Resist Updat.
10:13–29. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chau BN, Cheng EH, Kerr DA and Hardwick
JM: Aven, a novel inhibitor of caspase activation, binds Bcl-xL and
Apaf-1. Mol Cell. 6:31–40. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kutuk O, Temel SG, Tolunay S and Basaga H:
Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xL. Eur
J Cancer. 46:2494–2505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Melzer IM, Fernandez SB, Bosser S, et al:
The Apaf-1-binding protein Aven is cleaved by Cathepsin D to
unleash its anti-apoptotic potential. Cell Death Differ.
19:1435–1445. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo JY, Yamada A, Kajino T, et al:
Aven-dependent activation of ATM following DNA damage. Curr Biol.
18:933–942. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esmaili AM, Johnson EL, Thaivalappil SS,
Kuhn HM, Kornbluth S and Irusta PM: Regulation of the ATM-activator
protein Aven by CRM1-dependent nuclear export. Cell Cycle.
9:3913–3920. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choi J, Hwang YK, Sung KW, et al: Aven
overexpression: association with poor prognosis in childhood acute
lymphoblastic leukemia. Leuk Res. 30:1019–1025. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eissmann M, Melzer IM, Fernandez SB, et
al: Overexpression of the anti-apoptotic protein AVEN contributes
to increased malignancy in hematopoietic neoplasms. Oncogene.
32:2586–2591. 2013. View Article : Google Scholar
|
|
15
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jo SK, Hong JY, Park HJ and Lee SK:
Anticancer activity of novel daphnane diterpenoids from daphne
genkwa through cell-cycle arrest and suppression of Akt/STAT/Src
signalings in human lung cancer cells. Biomol Ther (Seoul).
20:513–519. 2012. View Article : Google Scholar
|
|
17
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Szakacs G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Krishna R and Mayer LD: Multidrug
resistance (MDR) in cancer. Mechanisms, reversal using modulators
of MDR and the role of MDR modulators in influencing the
pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 11:265–283.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lothstein L, Israel M and Sweatman TW:
Anthracycline drug targeting: cytoplasmic versus nuclear - a fork
in the road. Drug Resist Updat. 4:169–177. 2001. View Article : Google Scholar
|
|
23
|
Stavrovskaya AA: Cellular mechanisms of
multidrug resistance of tumor cells. Biochemistry (Mosc).
65:95–106. 2000.
|
|
24
|
El Maalouf G, Le Tourneau C, Batty GN,
Faivre S and Raymond E: Markers involved in resistance to
cytotoxics and targeted therapeutics in pancreatic cancer. Cancer
Treat Rev. 35:167–174. 2009. View Article : Google Scholar
|
|
25
|
Tamburrino A, Piro G, Carbone C, Tortora G
and Melisi D: Mechanisms of resistance to chemotherapeutic and
anti-angiogenic drugs as novel targets for pancreatic cancer
therapy. Front Pharmacol. 4:562013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
